The intranasal dexmedetomidine plus ketamine for procedural sedation in children, adaptive randomized controlled non-inferiority multicenter trial (Ketodex): a statistical analysis plan

• Published in: Current controlled trials in cardiovascular medicine Vol. 22; no. 1; p. 15
• Main Authors: Heath, Anna, Rios, Juan David, Pullenayegum, Eleanor, Pechlivanoglou, Petros, Offringa, Martin, Yaskina, Maryna, Watts, Rick, Rimmer, Shana, Klassen, Terry P, Coriolano, Kamary, Poonai, Naveen
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2021; BioMed Central; BMC
• Subjects: Anesthesia; Bayesian adaptive design; Caregivers; Children; Closed reduction; Data collection; Dexmedetomidine; Dosage and administration; Enrollments; Injuries; Intranasal ketodex; Ketamine; Length of stay; Medical records; Non-inferiority trial; Orthopedics; Pediatric closed reduction; Pediatrics; Procedural sedation and analgesia; Statistical analysis; Statistical analysis plan; Testing; Update; Canada; Bayesian adaptive design; Pediatric closed reduction; Statistical analysis plan; Non-inferiority trial; Procedural sedation and analgesia; Intranasal ketodex
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-020-04946-3

Procedural sedation and analgesia (PSA) is frequently required to perform closed reductions for fractures and dislocations in children. Intravenous (IV) ketamine is the most commonly used sedative agent for closed reductions. However, as children find IV insertion a distressing and painful procedure, there is need to identify a feasible alternative route of administration. There is evidence that a combination of dexmedetomidine and ketamine (ketodex), administered intranasally (IN), could provide adequate sedation for closed reductions while avoiding the need for IV insertion. However, there is uncertainty about the optimal combination dose for the two agents and whether it can provide adequate sedation for closed reductions. The Intranasal Dexmedetomidine Plus Ketamine for Procedural Sedation (Ketodex) study is a Bayesian phase II/III, non-inferiority trial in children undergoing PSA for closed reductions that aims to address both these research questions. This article presents in detail the statistical analysis plan for the Ketodex trial and was submitted before the outcomes of the trial were available for analysis. The Ketodex trial is a multicenter, four-armed, randomized, double-dummy controlled, Bayesian response adaptive dose finding, non-inferiority, phase II/III trial designed to determine (i) whether IN ketodex is non-inferior to IV ketamine for adequate sedation in children undergoing a closed reduction of a fracture or dislocation in a pediatric emergency department and (ii) the combination dose for IN ketodex that provides optimal sedation. Adequate sedation will be primarily measured using the Pediatric Sedation State Scale. As secondary outcomes, the Ketodex trial will compare the length of stay in the emergency department, time to wakening, and adverse events between study arms. The Ketodex trial will provide evidence on the optimal dose for, and effectiveness of, IN ketodex as an alternative to IV ketamine providing sedation for patients undergoing a closed reduction. The data from the Ketodex trial will be analyzed from a Bayesian perspective according to this statistical analysis plan. This will reduce the risk of producing data-driven results introducing bias in our reported outcomes. ClinicalTrials.gov NCT04195256 . Registered on December 11, 2019.